Seroprevalence of IgG antibodies to pertussis toxin in children and adolescents in Estonia

Highlights • The level of IgG GMC is highest after immunisation, decreases rapidly thereafter. • The level of PT IgG GMC is higher after primo- as compared to booster vaccination. • Half of the study subjects have anti-PT IgG concentration at an undetectable level. • Low anti-PT IgG level by ELISA d...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2014-09, Vol.32 (41), p.5311-5315
Main Authors: Jõgi, Piia, Oona, Marje, Toompere, Karolin, Leedo, Sirje, Epstein, Jevgenia, Lutsar, Irja
Format: Article
Language:English
Subjects:
Adolescent
Age
Allergy and Immunology
Antibodies, Bacterial - blood
Applied microbiology
Bacterial diseases
Biological and medical sciences
Child
Children & youth
Confidence intervals
Cross-Sectional Studies
Disease
Ent and stomatologic bacterial diseases
Estonia - epidemiology
Fundamental and applied biological sciences. Psychology
Hospitals
Human bacterial diseases
Humans
Immunization
Immunoglobulin G - blood
Infections
Infectious diseases
Laboratories
Medical sciences
Methods
Microbiology
Pertussis Toxin - immunology
Pertussis Vaccine - therapeutic use
Population
Prevalence
Sample size
Seroepidemiologic Studies
Studies
Toxins
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Whooping cough
Whooping Cough - epidemiology
Whooping Cough - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • The level of IgG GMC is highest after immunisation, decreases rapidly thereafter. • The level of PT IgG GMC is higher after primo- as compared to booster vaccination. • Half of the study subjects have anti-PT IgG concentration at an undetectable level. • Low anti-PT IgG level by ELISA does not necessarily mean missing protection. • The infection rate is 60 times higher than notified incidence of pertussis.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2014.07.066